Eric Tran
YOU?
Author Swipe
View article: CD39+CD103+ selected CD8+ tumor infiltrating lymphocytes for the treatment of solid tumors 3905
CD39+CD103+ selected CD8+ tumor infiltrating lymphocytes for the treatment of solid tumors 3905 Open
Description CD39+ CD103 + (double positive, DP) CD8+ T cells are primarily found in solid tumors and are enriched for tumor-reactive cells. These cells exhibit an exhausted phenotype characterized by elevated expression of CD39, PD-1, CTLA…
View article: 163 Unveiling the non-canonical dark immunopeptidome of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) using mass spectrometry and watchmaker total RNA-Seq
163 Unveiling the non-canonical dark immunopeptidome of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) using mass spectrometry and watchmaker total RNA-Seq Open
View article: Multi-cancer comparative multi-omics approach reveals a permissive tumor microenvironment in renal cell carcinoma through accumulation of exhausted CD8+ and CD4+CD8+ double positive T cells 2661
Multi-cancer comparative multi-omics approach reveals a permissive tumor microenvironment in renal cell carcinoma through accumulation of exhausted CD8+ and CD4+CD8+ double positive T cells 2661 Open
Description Introduction Renal cell carcinoma (RCC) is responsive to immunotherapy despite having a low tumor mutational burden. Interestingly, the degree of CD8+ T cell infiltration in RCC negatively correlates with outcomes, suggesting t…
View article: 592 Phase I study: CD39 <sup>+</sup> CD103 <sup>+</sup> CD8 <sup>+</sup> selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors
592 Phase I study: CD39 <sup>+</sup> CD103 <sup>+</sup> CD8 <sup>+</sup> selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors Open
View article: Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients
Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients Open
T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether T cells targeting mutant KRAS that are capable of killing tumor cells can be identified from pe…
View article: 1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy
1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy Open
View article: 156 Dark immunopeptidome of head and neck squamous cell carcinoma in serial cell lines from a single patient during multimodality treatment time-course
156 Dark immunopeptidome of head and neck squamous cell carcinoma in serial cell lines from a single patient during multimodality treatment time-course Open
View article: 1109 Engineering T cells with CD40-based chimeric receptors to enhance adoptive T cell therapy
1109 Engineering T cells with CD40-based chimeric receptors to enhance adoptive T cell therapy Open
View article: 152 Detection of PIK3CA mutation-derived neoepitopes from cancer cell lines
152 Detection of PIK3CA mutation-derived neoepitopes from cancer cell lines Open
View article: More T cell receptors to the RAScue in cancer?
More T cell receptors to the RAScue in cancer? Open
Treatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRs to u…
View article: 149 Simultaneous identification of KRAS mutation-carrying multiple neoepitopes by differential ion mobility-assisted targeted-mass spectrometry
149 Simultaneous identification of KRAS mutation-carrying multiple neoepitopes by differential ion mobility-assisted targeted-mass spectrometry Open
Background Extracellularly presented HLA class I antigen (immunopeptide) is one of the central mediators for cancer immunity. Immunopeptidomics, an analysis that directly identifies immunopeptides by mass spectrometry (MS), is the sole tec…
View article: 142 Detection of KRAS G12D/G12V neoepitopes expressed by cancer cell lines using LC-MS/MS
142 Detection of KRAS G12D/G12V neoepitopes expressed by cancer cell lines using LC-MS/MS Open
Background The targeting of mutated neoantigens with T-cell receptor (TCR) based therapies represents a promising strategy to treat cancer. Proof of concept for this approach recently was demonstrated in a patient with metastatic pancreati…
View article: Supplementary Figures and Tables 3, 5 and 6 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Supplementary Figures and Tables 3, 5 and 6 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy Open
Supplementary Figures 1-3 and Tables 1, 3, 4 and 6
View article: Supplementary Table 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Table 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Supplementary Table 2
View article: Supplementary Figure 1 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Figure 1 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Phenotypic analysis of the CD4 compartment in patients with CRLM
View article: Supplementary Table 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Table 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Supplementary Table 2
View article: Data from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Data from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Microsatellite-stable (MSS) colorectal cancers are characterized by low mutation burden and limited immune-cell infiltration and thereby respond poorly to immunotherapy. Here, we report a case of metastatic MSS colorectal cancer with a rob…
View article: Supplementary Table 3 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Table 3 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Supplementary Table 3
View article: Data from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Data from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy Open
Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) can mediate responses in some patients with metastatic epithelial cancer. Identifying gene signatures associated with successful ACT might enable the development of imp…
View article: Supplementary Table S5 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Supplementary Table S5 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy Open
Supplementary Table S5
View article: Supplementary Table 3 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Table 3 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Supplementary Table 3
View article: Supplementary Figure 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Figure 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Expression levels of genes involved in the MHC class I pathway in the primary tumor and CRLM of patient CRI 3280
View article: Data from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Data from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Microsatellite-stable (MSS) colorectal cancers are characterized by low mutation burden and limited immune-cell infiltration and thereby respond poorly to immunotherapy. Here, we report a case of metastatic MSS colorectal cancer with a rob…
View article: Supplementary Table S2 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Supplementary Table S2 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy Open
Supplementary Table S2
View article: Supplementary Table 1 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Table 1 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Supplementary Table 1
View article: Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer Open
Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we…
View article: Supplementary Table S2 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Supplementary Table S2 from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy Open
Supplementary Table S2
View article: Supplementary Figure 1 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Figure 1 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Phenotypic analysis of the CD4 compartment in patients with CRLM
View article: Data from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy
Data from Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy Open
Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) can mediate responses in some patients with metastatic epithelial cancer. Identifying gene signatures associated with successful ACT might enable the development of imp…
View article: Supplementary Figure 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens
Supplementary Figure 2 from Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens Open
Expression levels of genes involved in the MHC class I pathway in the primary tumor and CRLM of patient CRI 3280